Introduction of new tests for CMV and EBV at NVRL in mid-July 2026 – please refer to website notification on the NVRL website, 19^th December 2025

Reason for Notification:

Further to the previous notice issued on 19th December 2025, the NVRL will be moving routine testing of plasma for CMV and EBV DNA to the Roche Cobas® system in mid July 2026.

At this time, the new test codes (CCMV and CEBV, respectively) will come into effect and testing will be performed on plasma samples ONLY.   All other sample types, including urine and BAL specimens, will continue to be tested via the existing Altona assay.

Please note, the new assays will have the following lower limits of quantification as standard

CMV: CCMV: 35 IU/ml

EBV: CEBV: 35 IU/ml
 

While performance of the new assays is comparable to the Altona tests, users may wish to consider sending additional samples from patients under active monitoring, to establish a new baseline.  Please contact the NVRL Clinical team if you have any queries.

Phone 01-7164401, and select option 2.

NVRL reference: CN-26-14